**Product:** Calphostin C

**ALTERNATE NAME:** (1R)-2-[12-(2R)-2-(Benzoyloxy)propyl]-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl]-1-methylerylcarbonic acid 4-hydroxyphenyl esterUCN 1028C; PKF115-584; Cal-C

**CATALOG #:** 2611-50, 100

**AMOUNT:** 50 µg, 100 µg

**STRUCTURE:**

**MOLECULAR FORMULA:** C_{44}H_{38}O_{14}

**MOLECULAR WEIGHT:** 790.76

**CAS No.** 121263-19-2

**APPEARANCE:** Dark red solid

**SOLUBILITY:** DMSO (~1 mg/ml) or EtOH (~1 mg/ml)

**PURITY:** >95% by HPLC

**STORAGE:** Store at -20°C. Protect from air and light

**DESCRIPTION:** A potent and highly specific cell-permeable protein kinase C (PKC) inhibitor. The inhibition of PKC is light-dependent. Also inhibits PKA, PKG, DAG kinase, phospholipase D1 and D2, myosin light chain kinase and c-Src. Anticancer compound. Inhibits cell proliferation and strongly induces apoptosis in vitro. Shown to directly and potently block L-type calcium channels. Calphostin C specifically inhibits contraction-stimulated glucose transport but not insulin-stimulated glucose transport in skeletal muscle. Also Wnt/β-catenin/lef-1 signaling inhibitor.


**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**RELATED PRODUCTS:**
- Bisindolylmaleimide I (Cat. No. 1945-1, 5)
- Bisindolylmaleimide I hydrochloride (Cat. No. 1947-1, 5)
- Chelerythrine chloride (Cat. No. 2064-5)
- Enzastaurin (Cat. No. 1619-1, 5)
- Fasudil Mono HCl (Cat. No. 1787-10, 50)
- Go6976 (Cat. No. 1711-500)
- EZSolution™ Go6976 (Cat. No. 1785-500)
- H-89 DiHCl (Cat. No. 1768-1, 5)
- K252a (Cat. No. 2013-500, 1000)
- KN-93, Water-Soluble (Cat. No. 1909-1, 5)
- PKC412 (Cat. No. 2052-1,5)
- Ro 31-8220 methanesulfonato (Cat. No. 1946-1, 5)
- Staurosporine (Cat. No. 1048-01, 1)
- EZSolution™ Staurosporine (Cat. No. 1745-01)
- Stauprimido (Cat. No. 1743-500)
- Tamoxifen citrate (Cat. No. 1551-1000)

**FOR RESEARCH USE ONLY! Not to be used in humans.**